ð¥ å
§ç§å°ç§èåç
Mechanistic Deep Dive
Biofilm on Prosthetic Material
- Adherence of organisms within minutes of implantation
- Polysaccharide intercellular adhesin (PIA), embp, accumulation-associated protein (Aap)
- Resistant to immune clearance + antibiotic penetration
- Surgery often necessary
Why Rifampin in Staph PVE
- Rifampin penetrates biofilm
- Concentrates in macrophages
- Adds significant efficacy when combined with cell wall agent
- Avoid monotherapy (rapid resistance)
- Wait until day 3-5 of effective therapy to start (avoid resistance development)
Recent Trials & Updates
POET Sub-Analysis (Stable PVE)
- Some applicability to stable PVE patients
- Practical for low-resource settings
PADIT (2019) â TYRX Envelope
- Polymeric envelope releases antibiotics
- â Major infection in high-risk CIED
- Approved for re-do, high-risk implants
2023 ESC IE Guidelines PVE Update
- Earlier imaging
- More PET-CT use
- Closer surgical evaluation
- Endocarditis team mandatory
Subcutaneous ICD (S-ICD) Outcomes
- Better infection profile
- Long-term durability emerging
- Selected indications (no pacing required, no anti-tachy pacing needs)
Micra Leadless Pacemaker
- Lower infection rate
- Right-sided only
- Limited indications (VVI)
TAVR Endocarditis Specifics
- Risk factors identified
- IE within 1 year: 0.5-1%
- Outcomes similar to surgical PVE
High-Yield Specialist Points
Surgical Approach to PVE
- Re-do sternotomy (carry higher morbidity)
- Root replacement if abscess
- Pulmonic autograft (Ross) in young selected
- Bioprosthetic preferred if AC contraindication
- Complete debridement of abscess
- Pericardial patch reconstruction
Mechanical vs Bioprosthetic for PVE Re-Replacement
- Patient + lesion considerations
- AC requirements
- Re-do risk
- Life expectancy
Annular Abscess Management
- Common with PVE
- Often requires root replacement
- High morbidity but life-saving
- Bentall procedure for aortic root abscess
Heart Block + PVE
- Annular abscess invading conduction
- Temporary pacing
- Permanent pacing post-surgery often
- Sub-Q ICD or epicardial leads if recurrent
LVAD Infection Comprehensive Management
- Driveline site care daily
- Daptomycin or vanc for empiric S. aureus suspicion
- Pseudomonas: anti-pseudomonal coverage
- Suppressive long-term antibiotics often used
- Pump exchange in severe pump pocket / pump
- Heart transplant if eligible
Fungal IE Specific
- Candida most common
- Aspergillus rare but severe
- Echinocandin first-line
- Long-term suppression with fluconazole
- Almost always need surgical valve replacement
- High mortality
Healthcare-Associated IE
- Catheter-related bloodstream infection
- Dialysis access
- IV drug use in hospital
- Mortality similar or higher than community-acquired
Anticoagulation in PVE
- Continue warfarin if on mechanical valve
- Risk of bleeding vs thrombosis weighed
- Hold briefly for surgery
- Bridge with heparin
Outcomes + Multidisciplinary Approach
- IE team: Class I (2023 ESC)
- Reduces mortality 30-40%
- Standardized care pathways
Future Therapies
- Bacteriophage therapy for resistant organisms (trials)
- CRISPR-based anti-biofilm
- New antibiotics: oritavancin, dalbavancin (long-acting glycopeptides), tedizolid
- Antimicrobial-coated implants: improving
Pearls
- Early PVE (< 12 mo): nosocomial (CoNS, S. aureus, fungi, GNR)
- Late PVE (> 12 mo): similar to NVE
- Staph PVE: nafcillin/vanc + gent + rifampin (biofilm penetration)
- Surgery indications more liberal for PVE than NVE
- FDG-PET-CT > 3 months post-implant
- CIED infection: complete extraction + IV antibiotics + re-implant contralateral
- TYRX envelope for high-risk CIED implants
- LVAD infection: long-term + multidisciplinary
- Subcutaneous ICD + leadless pacemaker for high infection risk